Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability

Target: C1QA, C3, C3AR1 (complement cascade) Composite Score: 0.419 Price: $0.39▼13.0% Citation Quality: Pending neuroinflammation Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.419

Top 87% of 1302 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B Mech. Plausibility 15% 0.62 Top 56%

C+ Evidence Strength 15% 0.55 Top 56%

C+ Novelty 12% 0.58 Top 83%

D Feasibility 12% 0.38 Top 85%

C Impact 12% 0.40 Top 94%

C+ Druggability 10% 0.55 Top 54%

D Safety Profile 8% 0.35 Top 89%

D Competition 6% 0.32 Top 97%

B Data Availability 5% 0.60 Top 51%

C+ Reproducibility 5% 0.58 Top 54%

Evidence

5 supporting | 6 opposing

Citation quality: 50%

Debates

3 sessions B+

Avg quality: 0.74

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodegeneration?

The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendrocytes, but the specific neutralization mechanisms are not explained. Understanding these pathways could reveal therapeutic targets for MS neurodegeneration. Gap type: unexplained_observation Source paper: Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. (None, None, PMID:33603230)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TREM2-SYK Signaling Axis Couples OxPC Recognition to Phagocytic Clearance

Score: 0.453 | Target: TREM2 (Triggering receptor expressed on myeloid cells 2) + SYK (spleen tyrosine kinase)

→ View full analysis & all 2 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that modulating C1QA, C3, C3AR1 (complement cascade) within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability starts from the claim that C1Q/C3 complement activation mediates the intersection of OxPC accumulation and synaptic loss. When microglia successfully neutralize OxPC via TREM2-APOE-ABCA1 axis, complement activation is suppressed and synapses are preserved. In aged microglia with impaired neutralization, OxPC drives C1Q secretion and C3 generation, opsonizing synapses for microglial phagocytosis via C3aR1. Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA, C3, C3AR1 (complement cascade) or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C3, C3AR1 (complement cascade) or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. Identifier 33603230. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. Identifier 37208177. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA, C3, C3AR1 (complement cascade) or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C3, C3AR1 (complement cascade) or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. Identifier 33603230. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. Identifier 37208177. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C3, C3AR1 (complement cascade) within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating C1QA, C3, C3AR1 (complement cascade) or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.55, novelty 0.58, feasibility 0.38, impact 0.40, mechanistic plausibility 0.62, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `C1QA, C3, C3AR1 (complement cascade)` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C3, C3AR1 (complement cascade) or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutralization produces diffusible signals (potentially complement) driving synaptic vulnerability. Identifier 33603230. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation. Identifier NA (computational). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways. Identifier 37208177. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed OxPC neutralization and excessive synaptic pruning through shared complement-mediated mechanism. Identifier NA. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic. Identifier NA. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.3948`, debate count `1`, citations `11`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C3, C3AR1 (complement cascade) in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting C1QA, C3, C3AR1 (complement cascade) within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Complement Activation"] --> B["C1q/C3b Opsonization"]
    B --> C["Synaptic Tagging"]
    C --> D["Microglial Phagocytosis"]
    D --> E["Synapse Loss"]
    F["C1QA Modulation"] --> G["Complement Cascade Block"]
    G --> H["Reduced Synaptic Tagging"]
    H --> I["Synapse Preservation"]
    I --> J["Cognitive Protection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

11 citations 11 with PMID Validation: 50% 5 supporting / 6 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 1GENE 1EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Established background model links SASP to complem…	Supporting	MECH	-	-	-	-	PMID:NA	-
Source paper demonstrates microglial neutralizatio…	Supporting	MECH	-	-	-	-	PMID:33603230	-
TREM2, APOE, and ABCA1 regulate cholesterol storag…	Supporting	MECH	-	-	-	-	PMID:NA (computational)	-
LGALS3 elevation would synergize with complement a…	Supporting	MECH	-	-	-	-	PMID:37208177	-
Hypothesis explains why aged microglia with impair…	Supporting	MECH	-	-	-	-	PMID:NA	-
C3AR1 antagonist (avacopan) and other complement i…	Opposing	CLIN	-	-	-	-	PMID:NA	-
Complement inhibitors (eculizumab, ravulizumab) te…	Opposing	MECH	-	-	-	-	PMID:NA	-
Causal direction is ambiguous - complement activat…	Opposing	MECH	-	-	-	-	PMID:NA	-
C1Q is primarily astrocyte-derived in synaptic pru…	Opposing	MECH	-	-	-	-	PMID:NA	-
Synaptic loss in MS gray matter may not be complem…	Opposing	MECH	-	-	-	-	PMID:NA	-
C1QA genetic variants are not strongly associated …	Opposing	GENE	-	-	-	-	PMID:NA	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providin…▼

Established background model links SASP to complement cascade amplification (C1Q/C3, confidence 0.70) providing a foundation mechanism that OxPC pathology would amplify

PMID:NA

Source paper demonstrates microglial neutralization of OxPC prevents neuronal death suggesting failed neutrali…▼

PMID:33603230

TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link bet…▼

TREM2, APOE, and ABCA1 regulate cholesterol storage (GO:0010885, FDR=8.9x10^-9) providing mechanistic link between lipid metabolism and complement regulation

PMID:NA (computational)

LGALS3 elevation would synergize with complement amplification through overlapping inflammatory pathways

PMID:37208177

Hypothesis explains why aged microglia with impaired TREM2-SYK signaling and elevated LGALS3 show both failed …▼

PMID:NA

✗ Opposing Evidence 6

C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinic…▼

C3AR1 antagonist (avacopan) and other complement inhibitors have failed to meet primary endpoints in AD clinical trials with minimal efficacy

PMID:NA

Complement inhibitors (eculizumab, ravulizumab) tested without meaningful cognitive benefit in AD

PMID:NA

Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downst…▼

Causal direction is ambiguous - complement activation could be primary driver with OxPC accumulation as downstream consequence

PMID:NA

C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may …▼

C1Q is primarily astrocyte-derived in synaptic pruning contexts, not microglial - microglial contribution may be indirect

PMID:NA

Synaptic loss in MS gray matter may not be complement-dependent - may be T-cell-mediated or excitotoxic

PMID:NA

C1QA genetic variants are not strongly associated with AD risk in GWAS unlike TREM2 or APOE suggesting complem…▼

C1QA genetic variants are not strongly associated with AD risk in GWAS unlike TREM2 or APOE suggesting complement is not convergent mechanism

PMID:NA

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-14 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistic Hypotheses: Microglial OxPC Neutralization in MS

1. ApoE-Mediated Lipid Sequestration and Efflux

Mechanism: Microglia upregulate apolipoprotein E (ApoE) as a lipid shuttle to bind and sequester toxic OxPC species, then utilize ABCA1/ABCG1 transporters to efflux these complexes. ApoE's 2-3 helix domain directly coordinates the oxidized fatty acid tails of OxPCs, preventing them from inserting into neuronal/oligodendrocyte membranes. This creates a microglial "lipid sink" that protects vulnerable myelinating cells.

Key Evidence: Microglial ApoE expression is dramati

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Mechanistic Hypotheses

Hypothesis 1: ApoE-Mediated Lipid Sequestration and Efflux

Strongest Specific Weakness: Missing Export Mechanism

The hypothesis proposes a "lipid sink" where ApoE binds OxPCs from injured cells and effluxes them via ABCA1/ABCG1. The critical mechanistic gap is explaining how OxPCs initially exit neurons or oligodendrocytes. ABCA1/ABCG1 are expressed at low levels on mature neurons and oligodendrocytes—they lack the machinery to export lipids to microglia. Microglia cannot "pull" lipids from viable cells against concentration gra

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Response: Microglial OxPC Neutralization in Neurodegeneration

1. Hypotheses with Highest Translational Potential

A. TREM2-Dependent Microglial Phagocytosis and Lipid Processing

This wasn't explicitly proposed but is the most actionable mechanism. TREM2 is expressed exclusively on microglia and macrophages, drives their survival and phagocytic capacity, and has loss-of-function variants that cause Nasu-Hakola disease (demyelinating neurodegeneration). TREM2 recognizes lipid antigens including oxidized phospholipids via its negatively-charged binding pocket. Therape

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"ranked_hypotheses":[{"rank":1,"title":"TREM2-Dependent Microglial Phagocytosis and Lipid Processing","mechanism":"TREM2 on microglia recognizes oxidized phospholipid epitopes on damaged cells, triggering phagocytosis and lysosomal degradation of OxPC-laden debris.","target_gene":"TREM2","confidence_score":0.75,"novelty_score":0.55,"feasibility_score":0.8,"impact_score":0.85,"composite_score":0.74,"testable_prediction":"Trem2-deficient mice crossed to cuprizone or MOG-EM model will show accumulation of OxPC deposits and worsened demyelination compared to controls.","skeptic_concern":"Direct

Price History

7d Trend

↔

Stable

7d Momentum

▲ 1.8%

Volatility

High

0.1455

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.431	▼ 3.9%	market_dynamics	2026-04-14 11:29
📊	Score Update	$0.449	▲ 9.9%	market_dynamics	2026-04-14 08:35
📄	New Evidence	$0.408	▼ 9.6%	market_dynamics	2026-04-14 08:02
💬	Debate Round	$0.451	▼ 14.5%	market_dynamics	2026-04-14 05:24
📊	Score Update	$0.528	▼ 10.1%	market_dynamics	2026-04-14 04:35
💬	Debate Round	$0.588	▲ 32.0%	market_dynamics	2026-04-14 03:20
📄	New Evidence	$0.445	▲ 70.5%	market_dynamics	2026-04-14 03:17
💬	Debate Round	$0.261	▼ 18.5%	market_dynamics	2026-04-14 01:36
📊	Score Update	$0.321		market_dynamics	2026-04-13 23:22